Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Johnson & Johnson, while primarily known as America's leading healthcare company, now employs nearly 7,000 digital specialists and data scientists.

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

The chief executive of Johnson & Johnson has warned that potential ... Joe Wolk said the administration’s investigation into drug imports, widely seen as a first step toward imposing levies ...

Officials at the Department of Health and Human Services have struggled to find records belonging to Dr. Tom Shimabukuro, the director of the CDC’s Immunization Safety Office.

Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60. The pharmaceutical giant reported sales of $ ...